CHEST 2025: INSIDE LOOK
COPD Case Discussions: Eosinophils as a Biomarker of Type 2 Inflammation That Predicts Therapeutic Response
October 20 from 2:30 pm – 3:15 pm CDT
Learning Theater 1
Sponsored by Regeneron & Sanofi.
Program Description
Blood eosinophil count can be a clinically valuable biomarker of type 2 inflammation in COPD, but is impacted by many factors. Join us for a case-based discussion on type 2 inflammation and how considering biomarkers can address exacerbations and lung function in patients with COPD. This interactive session challenges you to decide what to do when triple therapy is not enough and introduces a treatment option that addresses sources of type 2 inflammation.
Presenters
Bryan Krajicek, MD, FCCP
Creighton University College of Medicine
Associate Professor of Medicine
Omaha, Nebraska
Jacqueline Sutter, DO
Thomas Jefferson University, Sidney Kimmel Medical College
Assistant Clinical Professor of Medicine
Philadelphia, Pennsylvania
